Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TARDBP | Q13148 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.42 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036507 | 0.85 | KMT2A (0.39) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL13495590 | 0.84 | KMT2A (0.48) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL9906234 | 0.79 | KMT2A (0.46) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL15034474 | 0.77 | BCHE (0.41) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL9906237 | 0.76 | HSD17B10 (0.38) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL15034449 | 0.72 | BCHE (0.37) | HSD17B10KMT2ACYP2C9MEN1NR1I2 | |
| SCHEMBL11858337 | 0.71 | HPGD (0.38) | KMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL9906238 | 0.71 | KMT2A (0.45) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL9906248 | 0.71 | KMT2A (0.44) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL1527926 | 0.69 | MAPT (0.53) | KMT2ACYP2C9MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130157986-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | INVASC THERAPEUTICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157986-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | INVASC THERAPEUTICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8198317-B2 | Methylenedioxy phenolic compounds and their use to treat disease | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198317-B2 | Methylenedioxy phenolic compounds and their use to treat disease | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120041025-A1 | Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof | CARMEL BIOSCIENCES, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041025-A1 | Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof | CARMEL BIOSCIENCES, INC. | 2012-02-16 | — | — | US | disclosed |
| WO-2010096677-A2 | DIHYDROLIPOIC ACID DERIVATIVES COMPRISING NITRIC OXIDE AND THERAPEUTIC USES THEREOF | INVASC THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100035849-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100035849-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035849-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | REN, PCSK9, ALOX12 | HSD17B10 163/4885KMT2A 1399/4885TARDBP 2677/4885 |
| US-20120041025-A1 | Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof | DLD, LDLR, ALOX15 | HSD17B10 281/4885KMT2A 4093/4885TARDBP 4436/4885 |
| US-20130157986-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | REN, PCSK9, COMT | HSD17B10 130/4885KMT2A 1673/4885TARDBP 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.